CHEYENNE, WY / ACCESSWIRE / August 31, 2020 / Yulong Eco-Materials Limited (OTC PINK:YECO) today announced that it has engaged Dr. Jason Sanders as Chief Medical Officer.
Dr. Sanders is an expert in the science and medicine of extracellular vesicles (EVs) including exosome-based diagnostic and therapeutic technology. As an honors graduate from Harvard University, Dr. Sanders concentrated in molecular biochemistry, cellular signaling and organic synthesis.
Dr. Sanders is a Board-Certified orthopedic surgeon and a member of the Alpha Omega Alpha medical honor society. After building a successful, reconstructive, orthopaedic surgical practice, Dr. Sanders expanded his focus to develop minimally invasive techniques for musculoskeletal, cutaneous and systemic tissue regeneration. Embracing a holistic view of regenerative medicine, Dr. Sanders has developed innovative, combined techniques using lasers, broadband light and other energy-based modalities with advanced biologics, such as mesenchymal stem cell therapy and stem cell exosomes, to regenerate many types of diseased or damaged tissues. As Chief Medical Officer, Dr. Sanders will advance scientific research on extracellular vesicles (EV) and will spearhead research and development of exosome-based clinical diagnostics and therapeutics.
CEO Daniel Mckinney, said “Dr. Sanders is the best of the best. EV Biologics has recruited one of the preeminent clinical and scientific minds in the EV and stem cell community to lead our research and product development. We have embarked on a new business journey into the forefront of medical science and will also retain experienced management from the pharma and biotech communities to lead our business.”
EV Biologics is currently negotiating to acquire a leading USA based stem cell company.
About the Company
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on bringing human mesenchymal “MSC” and other stem cell and cell-derived products to market in the cosmetic and biopharmaceutical spaces. Initially, these novel and unique products will be specifically provided to the international clinical research community including universities and physicians and will be targeted to the aesthetic and regenerative medicine markets. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in our superior products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.
This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company’s financial position and business strategy. The words or phrases “plans,” “would be,” “will allow,” “intends to,” “may result,” “are expected to,” “will continue,” “anticipates,” “expects,” “estimate,” “project,” “indicate,” “could,” “potentially,” “should,” “believe,” “think,” “considers” or similar expressions are intended to identify “forward-looking statements.” These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
YECO has 6.21 million shares issued and outstanding with a float of 1,016,375 shares.
For more information on EV Biologics please visit:
SOURCE: Yulong Eco-Materials Limited